Alector (ALEC) Common Equity (2018 - 2026)
Alector's (ALEC) quarterly Common Equity came in at -$10.0 million in Q2 2026, down 114.01% year-over-year from $71.2 million in Q2 2025, and down 196.03% quarter-over-quarter from $10.4 million in Q1 2026.
Analysis
Alector (ALEC) Common Equity (2018 - 2026) Analysis & Trends
Alector (ALEC) has reported Common Equity for 9 consecutive years, with -$10.0 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Common Equity fell 114.01% year-over-year to -$10.0 million in Q2 2026; TTM through Jun 2026 was -$10.0 million, a 114.01% decrease from a year earlier, with the FY2025 full-year figure at $30.6 million, down 75.83% from the prior year.
- Common Equity was -$10.0 million for Q2 2026 at Alector, down from $10.4 million in the prior quarter.
- Over five years, Common Equity peaked at $288.5 million in Q2 2022 and troughed at -$10.0 million in Q2 2026.
- A 5-year average of $140.5 million and a median of $142.4 million in 2023 frame the typical range for Common Equity.
- Across the five-year window, Common Equity jumped 56.36% in 2022 and plunged 114.01% in 2026, its largest moves.
- Over 5 years, Common Equity stood at $214.4 million in 2022, then tumbled by 37.44% to $134.2 million in 2023, then retreated by 5.48% to $126.8 million in 2024, then sank by 75.83% to $30.6 million in 2025, then tumbled by 132.53% to -$10.0 million in 2026.
- The last three Common Equity figures came in at -$10.0 million (Q2 2026), $10.4 million (Q1 2026), and $30.6 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 11.69 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 11.83 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 20.25 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 31.71 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 8.42 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 6.76 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 1.35 Bn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 18.85 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Alector | 274.68 Mn | 101.88 Mn | - | -9.97 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -9.97 Mn |
| Mar 31, 2026 | 10.38 Mn |
| Dec 31, 2025 | 30.65 Mn |
| Sep 30, 2025 | 57.71 Mn |
| Jun 30, 2025 | 71.18 Mn |
| Mar 31, 2025 | 94.61 Mn |
| Dec 31, 2024 | 126.80 Mn |
| Sep 30, 2024 | 118.93 Mn |
| Jun 30, 2024 | 150.57 Mn |
| Mar 31, 2024 | 178.91 Mn |
| Dec 31, 2023 | 134.16 Mn |
| Sep 30, 2023 | 162.56 Mn |
| Jun 30, 2023 | 196.31 Mn |
| Mar 31, 2023 | 183.02 Mn |
| Dec 31, 2022 | 214.44 Mn |
| Sep 30, 2022 | 253.10 Mn |
| Jun 30, 2022 | 288.52 Mn |
| Mar 31, 2022 | 267.54 Mn |
| Dec 31, 2021 | 300.72 Mn |
| Sep 30, 2021 | 335.89 Mn |